The pharmacology and clinical use of caspofungin (Q36788428)

16 August 2017

1 reference

title

The pharmacology and clinical use of caspofungin (English)

1 reference

16 August 2017

1 reference

William W Hope

1

0 references

Shmuel Shoham

series ordinal

2

object named as

Shmuel Shoham

1 reference

16 August 2017

3

Thomas J Walsh

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Drug Metabolism & Toxicology

16 August 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

language of work

1 reference

16 August 2017

volume

3

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

263-274

1 reference

Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Comparison of antifungal treatments for murine fusariosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

The yeast protein kinase C cell integrity pathway mediates tolerance to the antifungal drug caspofungin through activation of Slt2p mitogen-activated protein kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Identification of yeast Rho1p GTPase as a regulatory subunit of 1,3-beta-glucan synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Fungal ß(1,3)-D-glucan synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

In vitro activity of 1,3-beta-D-glucan synthase requires the GTP-binding protein Rho1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Cell shape determination: a pivotal role for Rho.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Glucan synthase complex of Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Effects of amphotericin B and caspofungin on histamine expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Hepatic uptake of the novel antifungal agent caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Potential for interactions between caspofungin and nelfinavir or rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Assessment of the paradoxical effect of caspofungin in therapy of candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Studies of the paradoxical effect of caspofungin at high drug concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

In vitro activity of caspofungin against Candida albicans biofilms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Caspofungin for Candida endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Candida prosthetic valve endocarditis cured by caspofungin therapy without valve replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Management of endogenous fungal endophthalmitis with voriconazole and caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Candida glabrata endophthalmitis treated successfully with caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Refractory candidal meningitis in an immunocompromised patient cured by caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Combination antifungal therapy for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

Echinocandin antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.263

21 January 2018

Identifiers

DOI

10.1517/17425255.3.2.263

1 reference

16 August 2017

1 reference